ORAGENICS INC
Business
Oragenics Inc is a development-stage biopharmaceutical company focused on researching and developing nasal delivery pharmaceutical therapies for neurological conditions and infectious diseases. The company's lead product candidate, ONP-002, is a synthetic neurosteroid designed to treat mild traumatic brain injury (concussion) via an intranasal breath-powered device that enables rapid direct delivery to the brain. ONP-002 has completed preclinical animal studies and Phase 1 clinical trials in healthy human subjects, with Phase 2a trials anticipated in Australia in Q1 2026. The company intends to pursue FDA approval and eventual commercialization through distribution and licensing agreements if regulatory approvals are obtained.
Summary from 10-K filed 2026-03-16
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 2 | 4 | 15 | 10 | 11 | |
| General and administrative | 7 | 6 | 5 | 4 | 5 | |
| Total operating expenses | 9 | 11 | 21 | 15 | 16 | |
| Loss from operations | −9 | −11 | −21 | −14 | −16 | |
| Interest income | 182,229 | 45,897 | 210,394 | 135,900 | 75,847 | |
| Interest expense | −785,930 | −29,828 | −30,591 | — | — | |
| Foreign currency exchange, net | −13,193 | −25,172 | — | — | — | |
| Total other income (expense), net | −616,894 | −9,103 | 249,166 | 132,379 | 59,404 | |
| Loss before income taxes | −10 | −11 | −21 | −14 | −16 | |
| Income tax benefit | 137,000 | — | — | — | — | |
| Net loss | −10 | −11 | −21 | −14 | −16 | |
| Basic net loss per share | −4.56 | −47.88 | −9.18 | −7.11 | −8.09 | |
| Diluted net loss per share | −4.56 | −47.88 | −9.18 | −7.11 | — | |
| Weight average shares outstanding, basic | 2 | 220,731 | 2 | 2 | 2 | |
| Weight average shares outstanding, diluted | 2 | 220,731 | 2 | 2 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 864,840 | 3 | 11 | 27 | |
| Short-term investments | 4 | — | — | — | — | |
| Interest receivable | 53,082 | — | — | — | — | |
| Prepaid expenses and other current assets | 2 | 607,670 | 382,273 | 3 | 434,699 | |
| Total current assets | 10 | 1 | 4 | 14 | 28 | |
| Total assets | 10 | 1 | 5 | 15 | 28 | |
| Accounts payable and accrued expenses | 2 | 1 | 1 | 1 | 947,574 | |
| Short-term notes payable, net of debt issuance costs | 227,348 | 328,528 | 312,703 | 267,640 | 303,416 | |
| Total liabilities | 2 | 2 | 2 | — | — | |
| Preferred stock, no par value; 50,000,000 shares authorized; 429,291 Series H and 7,488,692 Series F outstanding at December 31, 2025, and 0 Series H and 7,488,692 Series F outstanding at December 31, 2024. | — | — | 2 | 2 | 3 | |
| Common stock, $0.001 par value; 350,000,000 shares authorized; 4,271,529 and 419,003 shares issued and outstanding at December 31, 2025, and December 31, 2024, respectively | 4,271 | 419 | 3,081 | 2,025 | 2,003 | |
| Additional paid-in capital | 235 | 217 | 208 | 197 | 195 | |
| Accumulated deficit | −227 | −217 | −206 | −186 | −171 | |
| Total stockholders equity (deficit) | 8 | −211,885 | 3 | 13 | 26 | |
| Total liabilities and stockholders equity (deficit) | 10 | 1 | 5 | 15 | 28 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Amortization of debt discount and closing costs | 771,437 | — | — | — | — | |
| Stock-based compensation expense | 642,364 | 516,049 | 1 | 742,203 | 2 | |
| Stock-based compensation recapture expense | −86,617 | — | — | — | — | |
| Common stock for services rendered | 126,140 | — | — | — | — | |
| Other receivables | −53,082 | — | — | 6,987 | −6,987 | |
| Prepaid expenses and other current assets | −1 | 2 | 2 | −2 | 508,576 | |
| Operating lease right of use assets | — | 9,811 | 337,629 | — | — | |
| Accounts payable and accrued expenses | 203,144 | −119,800 | 25,798 | 176,625 | 10,554 | |
| Change in operating lease liabilities | — | −9,811 | −347,075 | — | — | |
| Net cash used in operating activities | −9 | −9 | −7 | −15 | −13 | |
| Borrowings on short-term notes payable | 2 | — | — | — | — | |
| Payments on short-term notes payable | −3 | −693,109 | −566,046 | −564,205 | −524,980 | |
| Net proceeds from issuance of preferred stock and warrants | 15 | — | — | — | — | |
| Net proceeds from issuance of common stock | 3 | 7 | — | 69,289 | 27 | |
| Net cash provided by financing activities | 17 | 6 | 283,880 | −494,916 | 23 | |
| Net increase (decrease) in cash and cash equivalents | 8 | −3 | −8 | −16 | 10 | |
| Interest paid | 22,353 | 29,828 | 30,591 | 9,290 | 15,756 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ORAGENICS INC's CIK number?
ORAGENICS INC's SEC CIK number is 0001174940 (1174940). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ORAGENICS INC's SEC filings?
All of ORAGENICS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.